CGEN COMPUGEN LTD Annual reports only
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1119774 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY161.1%
TTM net income YoY348.4%
TTM EPS YoY337.5%
Revenue 3-yr CAGR113.3%
Net income 3-yr CAGR—
Margins
Gross margin87.3%
Operating margin43.1%
Net margin48.6%
FCF margin43.1%
EBITDA margin43.7%
Returns
ROE44.8%
ROA26.0%
ROIC (approx.)128.1%
Asset turnover0.54x
Leverage & solvency
Liabilities / assets34.4%
Debt / equity0.00x
Current ratio6.56x
Interest coverage1,118.79x
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio2.7%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $72.76M | $27.86M | $33.46M | $7.50M | $6.00M |
| Cost of revenue | $9.25M | $7.93M | $2.00M | $975,000 | $680,000 |
| Gross profit | $63.51M | $19.93M | $31.45M | $6.53M | $5.32M |
| R&D expense | $22.76M | $24.81M | $34.47M | $30.65M | $28.69M |
| SG&A expense | $8.89M | $9.44M | $9.73M | $10.32M | $10.86M |
| Operating income | $31.33M | -$14.89M | -$12.99M | -$35.37M | -$35.07M |
| Interest expense | $28,000 | $34,000 | $31,000 | $27,000 | $25,000 |
| Pretax income | $35.40M | -$9.71M | -$9.78M | -$33.64M | -$34.20M |
| Income tax | $54,000 | $4.52M | $8.97M | $58,000 | $0 |
| Net income | $35.34M | -$14.23M | -$18.75M | -$33.69M | -$34.20M |
| EBITDA | $31.80M | -$14.40M | -$12.52M | -$34.89M | -$34.61M |
| EPS (basic) | 0.38 | -0.16 | -0.21 | -0.39 | -0.41 |
| EPS (diluted) | 0.38 | -0.16 | -0.21 | -0.39 | -0.41 |
| Weighted avg. shares (diluted) | 93.82M | 89.53M | 87.63M | 86.56M | 84.20M |
| Balance sheet | |||||
| Cash & equivalents | $90.60M | $18.23M | $13.89M | $11.42M | $8.51M |
| Short-term investments | $9.28M | $23.63M | $11.74M | $0 | — |
| Receivables | — | $0 | $61.00M | $0 | — |
| Current assets | $148.02M | $106.00M | $114.58M | $86.12M | $123.22M |
| PP&E, net | $681,000 | $852,000 | $1.22M | $1.53M | $1.66M |
| Total assets | $156.57M | $115.00M | $121.33M | $94.18M | $132.16M |
| Current liabilities | $22.57M | $20.16M | $26.27M | $11.92M | $17.10M |
| Total liabilities | $53.84M | $60.08M | $55.77M | $16.50M | $25.47M |
| Shareholders' equity | $102.73M | $54.91M | $65.56M | $77.68M | $106.69M |
| Shares outstanding | 94.55M | 89.54M | 89.24M | 86.62M | 86.43M |
| Cash flow statement | |||||
| Operating cash flow | $31.63M | $49.60M | -$35.89M | -$34.11M | -$22.69M |
| Capital expenditure | $306,000 | $118,000 | $172,000 | $477,000 | $292,000 |
| Free cash flow | $31.33M | $49.49M | -$36.06M | -$34.59M | -$22.98M |
| Investing cash flow | $30.00M | -$46.25M | $35.51M | $37.06M | $6.62M |
| Financing cash flow | $10.60M | $554,000 | $3.08M | $353,000 | $16.84M |
| Depreciation & amortization | $475,000 | $486,000 | $476,000 | $482,000 | $461,000 |
| Stock-based compensation | $1.88M | $3.02M | $3.55M | $4.33M | $4.28M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.